Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has secured an exclusive option and license agreement utilizing PolyTherics' site-specific TheraPEG™ PEGylation technology to develop NU400, a long-acting version of Nuron's proprietary recombinant human interferon beta-1b (NU100). PEGylating NU100 can also potentially improve other properties including its solubility, stability and safety profile. NU100 is poised to enter Phase 3 clinical studies in 2011 based on recent positive regulatory advice from the European Medicines Agency (EMEA).
"In the last year Nuron has acquired products or licensed technologies to build our pipeline of four exciting programs to realize our vision of bringing better biologics to market with enhanced product profiles for better health of patients," commented Shankar Musunuri, PhD, MBA, Chief Executive Officer and Founder of Nuron Biotech. "This new program, NU400, is especially exciting for us in that it further enhances the product profile of our lead program for Relapse Remitting Multiple Sclerosis (RRMS) and supports long-term life cycle strategy in the MS area."
Menopause found to shape initial symptoms and comorbidities in multiple sclerosis